Pertuzumab biosimilar - EirGenix
Alternative Names: EG-1206A; PerjetaLatest Information Update: 27 Nov 2023
At a glance
- Originator EirGenix
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Breast cancer